ReviewCurrent molecular medicine2010
Osteopontin: an effector and an effect of tumor metastasis.
Review in Current molecular medicine, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
72 citing papers in PubMed, 138 citations in OpenAlex.
- Serum Osteopontin Enhances Hepatocellular Carcinoma Diagnosis and Predicts Anti-PD-L1 Immunotherapy Benefit.Journal of hepatocellular carcinoma · 2025Article
- Development of a phenotypic screening assay to measure activation of cancer-associated fibroblasts.Frontiers in pharmacology · 2025Article
- Recent Advances in Biosensor Technology for Early-Stage Detection of Hepatocellular Carcinoma-Specific Biomarkers: An Overview.Diagnostics (Basel, Switzerland) · 2024Review
- Exploring the multifaceted role of obesity in breast cancer progression.Frontiers in cell and developmental biology · 2024Review
- Interleukin-6 in Hepatocellular Carcinoma: A Dualistic Point of View.Biomedicines · 2023Review
- Single-cell transcriptome analysis reveals liver injury induced by glyphosate in mice.Cellular & molecular biology letters · 2023Article
- Involvement of microRNAs and their potential diagnostic, therapeutic, and prognostic role in hepatocellular carcinoma.Journal of clinical laboratory analysis · 2022Review
- The Role of Extracellular Matrix Proteins in Breast Cancer.Journal of clinical medicine · 2022Review
- Lactate: A regulator of immune microenvironment and a clinical prognosis indicator in colorectal cancer.Frontiers in immunology · 2022Article
- Risk Factors and Biomarkers for Chronic Hepatitis B Associated Hepatocellular Carcinoma.International journal of molecular sciences · 2021Review
- Review
- Switching Homes: How Cancer Moves to Bone.International journal of molecular sciences · 2020Review
- Canine prostatic cancer cell line (LuMa) with osteoblastic bone metastasis.The Prostate · 2020Article
- Regulation of Osteosclerosis by Inoculated Cd133JBMR plus · 2019Article
- Adipocyte p62/SQSTM1 Suppresses Tumorigenesis through Opposite Regulations of Metabolism in Adipose Tissue and Tumor.Cancer cell · 2018Article
- Osteopontin Promotes Protective Antigenic Tolerance against Experimental Allergic Airway Disease.Journal of immunology (Baltimore, Md. : 1950) · 2018Article
- Accounting for tumor heterogeneity when using CRISPR-Cas9 for cancer progression and drug sensitivity studies.PloS one · 2018Article
- Osteopontin is involved in TLR4 pathway contributing to ovarian cancer cell proliferation and metastasis.Oncotarget · 2017Article
- Article
- Osteopontin Deficiency Suppresses Intestinal Tumor Development in Apc-Deficient Min Mice.International journal of molecular sciences · 2017Article
12 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Osteopontin (OPN) is a matricellular protein that is produced by multiple tissues in our body and is most abundant in bone. It is also produced by cancer cells and plays a determinative role in the growth, progression and metastasis of cancer. Clinically, OPN has been reported to be upregulated in tumor cells per se; this is also reflected by increased levels of OPN in the circulation. Thus, increased OPN levels the plasma are an effect of tumor growth and progression. Functionally, high OPN levels are determinative of higher incidence of bone metastases in mouse models and are clinically correlated with metastatic bone disease and bone resorption in advanced breast cancer patients. Several research efforts have been made to therapeutically target and inhibit the activities of OPN. In this article we have reviewed OPN in its role as an effector of critical steps in tumor progression and metastasis, with a particular emphasis on its role in facilitating bone metastasis of breast cancer. We have also addressed the role of the host-derived OPN in influencing the malignant behavior of the tumor cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.